Daiwa Capital Markets America’s BioMarin Pharmaceuticals BMRN Stock Holding History

Daiwa Capital Markets America’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q4	$310K	Buy	+4,400	New	+$299K	﹤0.01%	524

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Daiwa Capital Markets America's BMRN Position: Q4 2013 in Review

Daiwa Capital Markets America opened a new position in BioMarin Pharmaceuticals (BMRN) in Q4 2013: 4,400 shares worth $310K. The stake represents ﹤0.01% of the portfolio and ranks #524 among its holdings.

307 funds tracked by Wall St. Rank hold BMRN as of Q4 2013.

Daiwa Capital Markets America held 4,400 shares of BioMarin Pharmaceuticals worth $310K as of Q4 2013.
BioMarin Pharmaceuticals was a new Daiwa Capital Markets America position in Q4 2013.
BioMarin Pharmaceuticals made up ﹤0.01% of Daiwa Capital Markets America's portfolio in Q4 2013, its #524 holding.
307 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2013.

Based on Daiwa Capital Markets America's 13F filing for Q4 2013, filed 13 Feb 2014.